Sandoz Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SANDOZ INC, and what generic alternatives to SANDOZ INC drugs are available?
SANDOZ INC has one hundred and forty-three approved drugs.
There are three US patents protecting SANDOZ INC drugs. There are seventeen tentative approvals on SANDOZ INC drugs.
There is one patent family member on SANDOZ INC drugs in one country and two hundred and fifty-eight supplementary protection certificates in sixteen countries.
Summary for Sandoz Inc
| International Patents: | 1 |
| US Patents: | 3 |
| Tradenames: | 117 |
| Ingredients: | 114 |
| NDAs: | 143 |
| Patent Litigation for Sandoz Inc: | See patent lawsuits for Sandoz Inc |
| PTAB Cases with Sandoz Inc as petitioner: | See PTAB cases with Sandoz Inc as petitioner |
Drugs and US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | OXALIPLATIN | oxaliplatin | INJECTABLE;INTRAVENOUS | 078812-001 | Aug 7, 2009 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | |||||
| Sandoz Inc | CEFTRIAXONE | ceftriaxone sodium | INJECTABLE;INJECTION | 065204-002 | May 3, 2005 | AP | RX | No | Yes | See Plans and Pricing | See Plans and Pricing | ||||
| Sandoz Inc | RASAGILINE MESYLATE | rasagiline mesylate | TABLET;ORAL | 201892-002 | Jul 27, 2018 | AB | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| Sandoz Inc | TOPOTECAN | topotecan hydrochloride | SOLUTION;INTRAVENOUS | 200199-002 | Feb 25, 2011 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | |||||
| Sandoz Inc | PIPERACILLIN AND TAZOBACTAM | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 203557-001 | Oct 29, 2014 | AP | RX | No | No | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Sandoz Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz Inc | TIMOLOL MALEATE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020963-002 | Oct 21, 1998 | 6,174,524*PED | See Plans and Pricing |
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,311,708 | See Plans and Pricing |
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | 5,196,404*PED | See Plans and Pricing |
| Sandoz Inc | TIMOLOL MALEATE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020963-001 | Oct 21, 1998 | 6,174,524*PED | See Plans and Pricing |
| Sandoz Inc | BETOPTIC | betaxolol hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019270-001 | Aug 30, 1985 | 4,342,783 | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SANDOZ INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | 2009-09-01 |
International Patents for Sandoz Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2505836 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Sandoz Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1003503 | SZ 30/2006 | Austria | See Plans and Pricing | PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN |
| 0300652 | C300117 | Netherlands | See Plans and Pricing | PRODUCT NAME: DEXMEDETOMIDINE, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH IN FARMACEUTISCH OPZICHT AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZ ONDER DEXMEDETOMIDINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/2/02/033/001 20020830 |
| 1746976 | LUC00026 | Luxembourg | See Plans and Pricing | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
| 0509752 | C990041 | Netherlands | See Plans and Pricing | PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306 |
| 0364417 | SPC/GB97/014 | United Kingdom | See Plans and Pricing | PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
